Evaluation of the clinical phenotype of patients with LRRK2 mutations and studying interventions to treat non-motor manifestations
Development of biomarkers in various bio-fluids using novel techniques and expanding investigations of genotype-phenotype correlations in movement disorders and the role of therapeutics.
Study of Hypophonia, the soft speech that is often a characteristic of Parkinson’s disease.
Demystifying neuromodulation of dysfunctional brain circuits in Parkinson’s disease patients with deep brain stimulation.
Abnormal neuroplasticity in movement disorders.
Biomarkers – Diagnosing rare forms of Parkinson’s disease. University of Toronto.
VPS35’s role in transporting proteins that help brain cells communicate. University of British Columbia.
Biomarkers – Bringing the brain back to a healthy balance. Toronto Western Research Institute, UHN.
Subthalamic deep brain stimulation in Parkinson’s disease: Effect on the mobility of patients and their caregiver. McGill University.
The interaction between PINK1 and the Mitochondrial Processing Peptidase: Defining the role of Mitochondrial import defects in Parkinson’s Disease. McGill University.
Establishing a new link between brain and body.
Evaluation of chloroquine as a disease-modifying treatment for Parkinson’s disease. University of Toronto.
Cognitive Impairment – The pulsating brain and its implications for Parkinson’s disease. University of Toronto (Sunnybrook).
A novel fMRI approach to investigating the pathophysiology of postural instability in Parkinson’s Disease. University of British Columbia.
Creation of a Novel Computerized MRI-Integrated 3-D Histochemical Atlas of Parkinson’s Disease Brain. Montreal Neurological Institute, McGill University.
Regulation of Parkin function by deubiquitination. McGill University.
Characterization and validation of pharmacologically-driven signalling pathways to lower alpha-synuclein: Implications for Parkinson disease. Ottawa Health Research Institute.